期刊
CURRENT DIABETES REPORTS
卷 16, 期 10, 页码 -出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11892-016-0793-8
关键词
Diabetes; Type 1; Autoimmunity; Prevention; Intervention; Clinical trials
资金
- National Institute of Diabetes and Digestive Kidney Diseases [K08 DK095995]
- Juvenile Diabetes Research Foundation [2-SRA-2016-202-S-B]
- Children's Diabetes Foundation
Type 1 diabetes (T1D) results from the immunemediated destruction of insulin-producing beta cells located within the pancreatic islets of Langerhans. The autoimmune process leads to a deficiency in insulin production and resultant hyperglycemia requiring lifelong treatment with insulin administration. T1D continues to dramatically increase in incidence, especially in young children. Substantial knowledge surrounding human disease pathogenesis exists, such that T1D is now predictable with the measurement of antibodies in the peripheral blood directed against insulin and other beta cell proteins. With the ability to predict, it naturally follows that T1D should be preventable. As such, over the last two decades, numerous well-controlled clinical trials have been completed attempting to prevent diabetes onset or maintain residual beta cell function after clinical onset, all providing relatively disappointing results. Here, we review the T1D prevention efforts, the current landscape of clinical therapies, and end with a discussion regarding the future outlook for preventing T1D.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据